Coeptis Therapeutics Holdings, Inc.
COEP
$13.21
-$0.445-3.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 263.60K | 62.90K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 263.60K | 62.90K | -- | -- | -- |
| Cost of Revenue | 90.40K | 45.20K | -- | -- | -- |
| Gross Profit | 173.20K | 17.70K | -- | -- | -- |
| SG&A Expenses | 10.52M | 8.57M | 6.72M | 7.26M | 8.76M |
| Depreciation & Amortization | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.15M | 11.25M | 10.05M | 11.26M | 17.02M |
| Operating Income | -12.88M | -11.19M | -10.05M | -11.26M | -17.02M |
| Income Before Tax | -12.60M | -11.30M | -10.88M | -11.62M | -16.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.60 | -11.30 | -10.88 | -11.62 | -16.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.23M | 1.43M | 1.06M | -- | -- |
| Net Income | -10.37M | -9.87M | -9.81M | -11.62M | -16.14M |
| EBIT | -12.88M | -11.19M | -10.05M | -11.26M | -17.02M |
| EBITDA | -11.79M | -10.14M | -9.05M | -10.26M | -16.02M |
| EPS Basic | -3.82 | -4.48 | -5.17 | -6.44 | -10.29 |
| Normalized Basic EPS | -2.06 | -2.49 | -2.97 | -4.01 | -6.43 |
| EPS Diluted | -3.82 | -4.48 | -5.17 | -6.44 | -10.29 |
| Normalized Diluted EPS | -2.06 | -2.49 | -2.97 | -4.01 | -6.43 |
| Average Basic Shares Outstanding | 10.82M | 8.99M | 7.70M | 7.34M | 6.68M |
| Average Diluted Shares Outstanding | 10.82M | 8.99M | 7.70M | 7.34M | 6.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |